The total migraine market in India is substantial and growing at the rate of 25 per cent per annum, the company informed the Bombay Stock Exchange on Thursday.
The company is expecting to garner a substantial market share in the first year of launch, it said.
As part of its continuing medical education programme, the company will organize seminars on the role of Rizatriptan in migraine management at Hyderabad, Mumbai, Chennai and Delhi during March and April, it added.